Cookies on this site

Abstract Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported. Clin Cancer Res; 19(20); 5546–8. ©2013 AACR.

More information

DOI

10.1158/1078-0432.ccr-13-2157

Type

Journal article

Publisher

American Association for Cancer Research (AACR)

Publication Date

15/10/2013

Volume

19

Pages

5546 - 5548

Total pages

2